informed consent
Item
has given written consent before any study related activity is performed. a study related activity is defined as any procedure that would not have been performed during the normal management of the patient.
boolean
C0021430 (UMLS CUI [1])
testosterone suppression
Item
has had sufficient testosterone suppression (as defined in the withdrawal criteria of fe200486 cs06) for at least 28 days.
boolean
C0563648 (UMLS CUI [1,1])
C0039601 (UMLS CUI [1,2])
withdrawn from other study
Item
has been withdrawn from study fe200486 cs06 due to an adverse event, failure to achieve at least 28 days of testosterone suppression, insufficient prostate-specific antigen (psa) suppression as defined in study fe200486 cs06 in the absence of concomitant rise in testosterone level or non-compliance with protocol required procedures.
boolean
C2349954 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
neoadjuvant hormonal therapy
Item
requires hormonal therapy for neoadjuvant purposes.
boolean
C0279025 (UMLS CUI [1,1])
C0600558 (UMLS CUI [1,2])
medication modifying testosterone
Item
requires treatment with any other drug modifying the testosterone level or function.
boolean
C0013227 (UMLS CUI [1,1])
C2066646 (UMLS CUI [1,2])
C0039601 (UMLS CUI [1,3])
radical prostatectomy or radiotherapy
Item
is considered to be a candidate for curative therapy, i.e., radical prostatectomy or radiotherapy, within 6 months after visit 1.
boolean
C0194810 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
severe asthma
Item
has a history of severe asthma requiring daily treatment with inhalation steroids, angioedema or anaphylactic reactions.
boolean
C0581126 (UMLS CUI [1])
hypersensitivity to investigational product
Item
has hypersensitivity towards any component of the investigational product.
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
cancer disease
Item
has had a cancer disease within the last 10 years except for prostate cancer, and surgically removed basocellular or squamous cell carcinoma of the skin.
boolean
C0006826 (UMLS CUI [1])
comorbidity
Item
has a clinically significant neurologic, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, dermatological or infectious disorder or any other condition, including excessive alcohol or drug abuse, which may interfere with trial participation or which may affect the conclusion of the study, as judged by the investigator.
boolean
C0009488 (UMLS CUI [1])
C1321605 (UMLS CUI [2,1])
C0439801 (UMLS CUI [2,2])
C0009488 (UMLS CUI [2,3])
laboratory abnormalities
Item
any clinically significant laboratory abnormalities which, in the judgment of the investigator, would interfere with the patient's participation in this study or evaluation of study results (liver transaminases and bilirubin must be within normal limits).
boolean
C1853129 (UMLS CUI [1])
mental incapacity or language barrier
Item
has a mental incapacity or language barrier precluding adequate understanding or co-operation.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0237167 (UMLS CUI [2])